Get the Stockscreener App
52.68
1.59%
-0.86
Moderna Inc stock is traded at $52.68, with a volume of 3.60M.
It is down -1.59% in the last 24 hours and down -12.48% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$53.54
Open:
$53.53
24h Volume:
3.60M
Relative Volume:
0.76
Market Cap:
$20.58B
Revenue:
$4.99B
Net Income/Loss:
$-5.87B
P/E Ratio:
-5.6342
EPS:
-9.35
Net Cash Flow:
$-3.98B
1W Performance:
-4.58%
1M Performance:
-12.48%
6M Performance:
-57.85%
1Y Performance:
-32.04%
1-Day Range:
$52.08
$54.32
1-Week Range:
$52.08
$55.65
52-Week Range:
$52.08
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (NASDAQ:MRNA) Reaches New 1-Year Low Following Analyst Downgrade - MarketBeat
Moderna is ‘show-me story’ heading into Q3 earnings - The Business Journals
Moderna’s Bancel Steps Down as Sales Chief, Keeps CEO Role - MSN
Moderna CEO Bancel steps down as sales chief, Bloomberg News reports - Marketscreener.com
Moderna CEO Bancel steps down as sales chief, Bloomberg Law reports - Marketscreener.com
Moderna stock touches 52-week low at $52.21 amid market shifts - Investing.com Canada
Should Moderna Stock Be In Your Portfolio Pre-Q3 Earnings? - Barchart
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - Quantisnow
Moderna is Now Oversold (MRNA) - Nasdaq
Moderna (NASDAQ:MRNA) Price Target Cut to $59.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
New York State Common Retirement Fund Sells 20,030 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer - Medical Dialogues
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Metagenomi to Contact Us to Have Their Losses Evaluated Today - GlobeNewswire Inc.
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by abrdn plc - MarketBeat
Moderna Inc. stock rises Friday, still underperforms market - MarketWatch
Moderna (MRNA) Stock Moves -0.66%: What You Should Know - Yahoo Finance
Moderna Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Moderna (MRNA): Expanding Horizons in Gene Editing and mRNA Vaccines - Yahoo Finance
December 13th Options Now Available For Moderna (MRNA) - Nasdaq
Is Moderna (NASDAQ:MRNA) Stock a Buy at Current Levels? - Yahoo Finance
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Meitav Investment House Ltd. Buys 111,475 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna to Present at Upcoming Conferences in November 2024 - Yahoo Finance
Moderna (MRNA) Scheduled to Post Earnings on Thursday - MarketBeat
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In 2024? - Insider Monkey
10 Worst Performing Stocks in S&P 500 in 2024 - Insider Monkey
International Assets Investment Management LLC Grows Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Moderna Board, Top Execs Sued Over Statements About RSV Vaccine - Bloomberg Law
Moderna Inc. stock rises Tuesday, still underperforms market - MarketWatch
Moderna (NASDAQ:MRNA) Trading Up 3.9%What's Next? - MarketBeat
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Moderna price target lowered to $60 from $105 at Evercore ISI - Yahoo Finance
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer - Yahoo Finance
Raymond James & Associates Raises Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Brass Hit With Investor Suit Over RSV Shot Claims - Law360
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Is Moderna Stock Trading Higher On Monday? - Yahoo Finance
Moderna Stock Price Target Slashed. It’s About Vaccines. - Barron's
Moderna: launches clinical trial in collaboration with Merck - Marketscreener.com
Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer - Marketscreener.com
MSD, Moderna start phase 3 adjuvant lung cancer trial - pharmaphorum
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC - BioSpace
Merck and Moderna launch phase 3 trial for lung cancer therapy - Investing.com UK
Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA - StreetInsider.com
14,100 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by E. Ohman J or Asset Management AB - MarketBeat
Shareholders of Moderna, Inc. Should Contact Levi & Korsinsky LLP Before October 08, 2024 to Discuss Your Rights – MRNA - MSN
WhatsApp lands Moderna in hot water with PMCPA - pharmaphorum
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Sep 09 '24 |
Sale |
73.57 |
551 |
40,539 |
18,154 |
0.20%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):